Request appointment
1283 York Avenue4th FloorNew York, NY 10065
Overview of Dr. Cristofanilli
Dr. Massimo Cristofanilli is an oncologist in New York, NY and is affiliated with New York-Presbyterian Hospital. He received his medical degree from Sapienza University of Rome and has been in practice 40 years. Dr. Cristofanilli accepts several types of health insurance, listed below. He is one of 403 doctors at New York-Presbyterian Hospital who specialize in Oncology. He also speaks multiple languages, including Italian. He has more than 100 publications and over 500 citings.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1993 - 1996
Sapienza University of RomeClass of 1986
Certifications & Licensure
NY State Medical License 2022 - 2027
IL State Medical License 2015 - 2026
PA State Medical License 2010 - 2016
TX State Medical License 1997 - 2010
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification Northwestern Meaningful Use Data Warehouse Application for Eligible Providers, Northwestern University, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Complete), Allscripts, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- Improved Surfactant-Assisted One-Pot Sample Preparation for Robust Convenient Single-Cell Proteomics.Reta Birhanu Kitata, Zhangyang Xu, Nadia Bayou, Rui Zhao, William B Chrisler
Journal of Proteome Research. 2026-08-07 - Inflammatory breast cancer: Improving research and care through the integration of preclinical evidence and technological advances.Eleonora Nicolo, Maroua Manai, Amr Soliman, Carolina Reduzzi, Massimo Cristofanilli
Critical Reviews in Oncology/hematology. 2026-08-06 - SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.Adam Brufsky, Yeon Hee Park, François-Clément Bidard, Erica L Mayer, Wolfgang Janni
The Oncologist. 2026-08-06
Journal Articles
- Minimal Residual Disease in Patients with Nonmetastatic Triple-Negative Breast CancerMassimo Cristofanilli, MD, JAMA Oncology
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerMassimo Cristofanilli, MD, The New England Journal of Medicine
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingWilliam J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health
Authored Content
- Minimal Residual Disease in Patients with Nonmetastatic Triple-Negative Breast CancerJuly 2020
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingAugust 2018
Press Mentions
'Liquid Biopsies' Alert Advanced Breast Cancer Patients When New Drugs Are NeededJune 1st, 2025- Switching to Experimental Drug Following Liquid Biopsy Detection of Breast Cancer Recurrence Enhances Patient OutcomesJune 1st, 2025
- Undiagnosed Cancer Could Be the Next Health Crisis — and We Aren’t ReadyDecember 12th, 2022
Committees
- Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present
Professional Memberships
- Fellow
- Member
- Member
Other Languages
- Italian
External Links
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
Amerihealth HMO
AmeriHealth PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOFirst Health PPO
Great West PPO
IBC Keystone HMO / POS
IBC Personal Choice PPO
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
